Department of Cardiology, 986th Hospital, Fourth Military Medical University, Xi'an, China.
Department of Cardiology, 986 Hospital, Fourth Military Medical University, Xi'an, China.
Bioengineered. 2022 Jan;13(1):1137-1148. doi: 10.1080/21655979.2021.2017696.
Angiotensin II-induced vascular smooth muscle cell (VSMC) remodeling and dysfunction is a major contributor to the development of hypertension. In spite of the low content of mitochondria and their low contribution to bioenergetics in VSMCs, recent studies have suggested that mitochondria play an important role in the regulation of VSMC function. However, the role of mitochondria in angiotensin II-induced VSMC dysfunction remains unknown. Here, we found that angiotensin II decreased the expression of Bcl-2-like protein 1 (Bcl-xL), a newly identified protein in inhibition of uncoupled proton flux in mitochondria through interaction with the β-subunit of ATP synthase, and uncoupled mitochondria in VSMCs both in vivo and in vitro. Overexpression of Bcl-xL restored the mitochondrial and VSMC function in response to angiotensin II treatment in vitro, suggesting that angiotensin II uncouples mitochondria through downregulation of Bcl-xL. Mechanistically, angiotensin II increased the expression of miR-140-5p, which targeted and downregulated Bcl-xL in VSMCs. Inhibition of miR-140-5p using antagomir-140-5p in vivo attenuated mitochondrial uncoupling and hypertension in angiotensin II-treated mice. These results suggested that upregulation of miR-140-5p uncouples mitochondria by targeting Bcl-xL in VSMCs in angiotensin II-induced hypertension, and miR-140-5p and Bcl-xL are potential targets for treatment of vascular dysfunction.
血管平滑肌细胞(VSMC)重塑和功能障碍是导致高血压的主要原因。尽管 VSMC 中的线粒体含量较低,对生物能量的贡献也较低,但最近的研究表明,线粒体在调节 VSMC 功能方面发挥着重要作用。然而,线粒体在血管紧张素 II 诱导的 VSMC 功能障碍中的作用尚不清楚。在这里,我们发现血管紧张素 II 降低了 Bcl-2 样蛋白 1(Bcl-xL)的表达,Bcl-xL 是一种新发现的蛋白,通过与 ATP 合酶的β亚基相互作用抑制线粒体中的未偶联质子流。血管紧张素 II 还在体内和体外减少了 VSMC 中线粒体的未偶联和 VSMC 功能。Bcl-xL 的过表达恢复了 VSMC 对血管紧张素 II 处理的线粒体和 VSMC 功能,提示血管紧张素 II 通过下调 Bcl-xL 使线粒体解偶联。在机制上,血管紧张素 II 增加了 miR-140-5p 的表达,miR-140-5p 在 VSMCs 中靶向并下调了 Bcl-xL。体内使用 miR-140-5p 的拮抗剂 antagomir-140-5p 可减轻血管紧张素 II 处理的小鼠中的线粒体解偶联和高血压。这些结果表明,血管紧张素 II 通过靶向 VSMC 中的 Bcl-xL 上调 miR-140-5p 导致线粒体解偶联,miR-140-5p 和 Bcl-xL 是治疗血管功能障碍的潜在靶点。